Restorgenex Corporation (RESX) 2.5400 $RESX
A Deep Look At RestorGenex RES-440 For Acne
Jason Napodano, CFA - at Seeking Alpha - Thu May 14, 3:00PM CDT
RestorGenex Reports First Quarter 2015 Financial Results
GlobeNewswire - Mon May 11, 3:06PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its financial results and cash balance for the first quarter ended March 31, 2015.
RestorGenex Issues Annual Letter to Stockholders
GlobeNewswire - Thu Apr 23, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, is pleased to present its Annual Letter to Stockholders from CEO, Stephen M. Simes.
RES-529 Offers Two Shots On Goal For RestorGenex
Jason Napodano, CFA - Seeking Alpha - Tue Apr 07, 1:05PM CDT
By Jason Napodano, CFA and David Bautz, Ph.D RestorGenex ( OTCQB:RESX ) is a specialty pharmaceutical company developing treatments for ophthalmology, oncology, and dermatology. The company has two proprietary compounds under development, RES-529...
RestorGenex Reports Corporate Highlights and Financial Results for 2014
GlobeNewswire - Mon Apr 06, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, reported on its cash balance as of December 31, 2014 and its financial results for the year ended December 31, 2014. The Company also completed several significant milestones during 2014, including the following highlights:
RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Mar 24, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Equities.com.
RestorGenex to Present at the Future Leaders in the Biotech Industry Conference
GlobeNewswire - Wed Mar 18, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the 22 Annual Future Leaders in the Biotech Industry Conference, being held Friday, March 20, 2015, in New York, NY. Mr. Simes will provide a corporate overview at 9:00am ET. The presentation will be webcast and available at https://www.webcaster4.com/Webcast/Page/818/7620.
RestorGenex to Present at BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 5:30AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, is scheduled to present at the 17 Annual BIO CEO & Investor Conference in New York City. Mr. Simes will provide a corporate overview on Tuesday, February 10, at 2:30pm ET. The presentation will be webcast and available at http://www.veracast.com/webcasts/bio/ceoinves...285519.cfm.
RestorGenex Granted Orphan Drug Designation for RES-529 for Treatment of Glioblastoma Multiforme
GlobeNewswire - Wed Jan 28, 6:00AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RES-529 for the treatment of glioblastoma multiforme. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan drug designation qualifies the sponsor of the product for a tax credit and seven years of marketing exclusivity.
RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways
GlobeNewswire - Fri Jan 23, 7:32AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that it presented scientific data on RES-529 for the treatment of glioblastoma multiforme (GBM) at the Keystone Symposia Series on PI 3-Kinase (PI3K) Signaling Pathways. The presentation titled "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme" was presented on January 16, 2015. RES-529 is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that is capable of dissociating both TORC1 and TORC2.
RestorGenex to Present at Noble Financial Capital Markets' Eleventh Annual Equity Conference
Business Wire - Fri Jan 16, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology, and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, will present a corporate update at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 20, 2014 at 10:00 am Eastern Standard Time.
RestorGenex to Present Glioblastoma Data at Keystone Conference on PI 3-Kinase Signaling Pathways in Disease Conference
Business Wire - Tue Jan 13, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that David Sherris, Ph.D., chief scientific officer of RestorGenex, will present scientific data on the Company's proprietary RES-529 program in oncology, focusing on glioblastoma multiforme entitled, "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme." Dr. Sherris's poster presentation at the Keystone Conference on PI 3-Kinase Signaling Pathways in Disease is scheduled for Friday, January 16, 2015 from 12:00 PM - 2:30 PM (PST) at the Fairmont Hotel Vancouver, Vancouver, British Columbia.
RestorGenex to Present at Biotech Showcase 2015
Business Wire - Wed Jan 07, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the Biotech Showcase 2015 in San Francisco, CA. Mr. Simes will provide a corporate overview on Tuesday, January 13, at 3:00 pm PST. The presentation will be webcast and available at http://edge.media-server.com/m/p/3bskmh3j and will be archived at www.restorgenex.com.
RestorGenex Announces Issuance of European Patent for its Dermatology Program
Business Wire - Mon Jan 05, 6:01AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that the European Patent Office has issued to RestorGenex European Patent No. 2364700 entitled "Compositions and Methods to Treat Skin Diseases Characterized by Cellular Proliferation and Angiogenesis." The patent is directed to use of RES-529, as well as other small molecules, for preventing or treating skin diseases, as well as on the composition of matter of RES-529. RES-529 is a first-in-class allosteric dissociative TORC1/TORC2 inhibitor of the PI3K pathway, and is RestorGenex's lead candidate in development for the treatment of diseases involving cell proliferation and angiogenesis.
RestorGenex EPS of -$0.18
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:17PM CST
RestorGenex Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 3:00PM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of September 30, 2014 and its financial results for the third quarter of 2014.
RestorGenex to Present at Conference on Targeting Ocular Disorders
Business Wire - Mon Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Chief Scientific Officer David Sherris, Ph.D., will present scientific data on the Company's proprietary RES-529 program in ophthalmology. Dr. Sherris's presentation at the Cambridge Healthtech Institute conference is scheduled for Monday, October 6, 2014 at 4:55 pm (EDT) at the Westin Boston Waterfront Hotel.
RestorGenex to Present at the AACR Conference on Targeting the PI3K-mTOR Network in Cancer
Business Wire - Mon Sep 15, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company initially focused on developing products for oncology, dermatology, ophthalmology and women's health, today announced that David Sherris, Ph.D., RestorGenex's chief scientific officer, will present scientific data on the Company's proprietary RES-529 program in oncology. Dr. Sherris' presentation at the American Association for Cancer Research Conference on Targeting the PI3K-mTOR Network in Cancer is scheduled for Monday, September 15, 2014 at 4:30 pm (EST) at the Sheraton Philadelphia Downtown Hotel, Philadelphia, Pennsylvania.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.
RestorGenex Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 3:05PM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of June 30, 2014 and its financial results for the second quarter of 2014.
A Deep Look At RestorGenex RES-440 For Acne
Jason Napodano, CFA - at Seeking Alpha - Thu May 14, 3:00PM CDT
RestorGenex Reports First Quarter 2015 Financial Results
GlobeNewswire - Mon May 11, 3:06PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its financial results and cash balance for the first quarter ended March 31, 2015.
RestorGenex Issues Annual Letter to Stockholders
GlobeNewswire - Thu Apr 23, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, is pleased to present its Annual Letter to Stockholders from CEO, Stephen M. Simes.
RES-529 Offers Two Shots On Goal For RestorGenex
Jason Napodano, CFA - Seeking Alpha - Tue Apr 07, 1:05PM CDT
By Jason Napodano, CFA and David Bautz, Ph.D RestorGenex ( OTCQB:RESX ) is a specialty pharmaceutical company developing treatments for ophthalmology, oncology, and dermatology. The company has two proprietary compounds under development, RES-529...
RestorGenex Reports Corporate Highlights and Financial Results for 2014
GlobeNewswire - Mon Apr 06, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, reported on its cash balance as of December 31, 2014 and its financial results for the year ended December 31, 2014. The Company also completed several significant milestones during 2014, including the following highlights:
RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Mar 24, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Equities.com.
RestorGenex to Present at the Future Leaders in the Biotech Industry Conference
GlobeNewswire - Wed Mar 18, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the 22 Annual Future Leaders in the Biotech Industry Conference, being held Friday, March 20, 2015, in New York, NY. Mr. Simes will provide a corporate overview at 9:00am ET. The presentation will be webcast and available at https://www.webcaster4.com/Webcast/Page/818/7620.
RestorGenex to Present at BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 5:30AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, is scheduled to present at the 17 Annual BIO CEO & Investor Conference in New York City. Mr. Simes will provide a corporate overview on Tuesday, February 10, at 2:30pm ET. The presentation will be webcast and available at http://www.veracast.com/webcasts/bio/ceoinves...285519.cfm.
RestorGenex Granted Orphan Drug Designation for RES-529 for Treatment of Glioblastoma Multiforme
GlobeNewswire - Wed Jan 28, 6:00AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RES-529 for the treatment of glioblastoma multiforme. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan drug designation qualifies the sponsor of the product for a tax credit and seven years of marketing exclusivity.
RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways
GlobeNewswire - Fri Jan 23, 7:32AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that it presented scientific data on RES-529 for the treatment of glioblastoma multiforme (GBM) at the Keystone Symposia Series on PI 3-Kinase (PI3K) Signaling Pathways. The presentation titled "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme" was presented on January 16, 2015. RES-529 is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that is capable of dissociating both TORC1 and TORC2.
RestorGenex to Present at Noble Financial Capital Markets' Eleventh Annual Equity Conference
Business Wire - Fri Jan 16, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology, and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, will present a corporate update at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 20, 2014 at 10:00 am Eastern Standard Time.
RestorGenex to Present Glioblastoma Data at Keystone Conference on PI 3-Kinase Signaling Pathways in Disease Conference
Business Wire - Tue Jan 13, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that David Sherris, Ph.D., chief scientific officer of RestorGenex, will present scientific data on the Company's proprietary RES-529 program in oncology, focusing on glioblastoma multiforme entitled, "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme." Dr. Sherris's poster presentation at the Keystone Conference on PI 3-Kinase Signaling Pathways in Disease is scheduled for Friday, January 16, 2015 from 12:00 PM - 2:30 PM (PST) at the Fairmont Hotel Vancouver, Vancouver, British Columbia.
RestorGenex to Present at Biotech Showcase 2015
Business Wire - Wed Jan 07, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the Biotech Showcase 2015 in San Francisco, CA. Mr. Simes will provide a corporate overview on Tuesday, January 13, at 3:00 pm PST. The presentation will be webcast and available at http://edge.media-server.com/m/p/3bskmh3j and will be archived at www.restorgenex.com.
RestorGenex Announces Issuance of European Patent for its Dermatology Program
Business Wire - Mon Jan 05, 6:01AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that the European Patent Office has issued to RestorGenex European Patent No. 2364700 entitled "Compositions and Methods to Treat Skin Diseases Characterized by Cellular Proliferation and Angiogenesis." The patent is directed to use of RES-529, as well as other small molecules, for preventing or treating skin diseases, as well as on the composition of matter of RES-529. RES-529 is a first-in-class allosteric dissociative TORC1/TORC2 inhibitor of the PI3K pathway, and is RestorGenex's lead candidate in development for the treatment of diseases involving cell proliferation and angiogenesis.
RestorGenex EPS of -$0.18
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:17PM CST
RestorGenex Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 3:00PM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of September 30, 2014 and its financial results for the third quarter of 2014.
RestorGenex to Present at Conference on Targeting Ocular Disorders
Business Wire - Mon Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Chief Scientific Officer David Sherris, Ph.D., will present scientific data on the Company's proprietary RES-529 program in ophthalmology. Dr. Sherris's presentation at the Cambridge Healthtech Institute conference is scheduled for Monday, October 6, 2014 at 4:55 pm (EDT) at the Westin Boston Waterfront Hotel.
RestorGenex to Present at the AACR Conference on Targeting the PI3K-mTOR Network in Cancer
Business Wire - Mon Sep 15, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company initially focused on developing products for oncology, dermatology, ophthalmology and women's health, today announced that David Sherris, Ph.D., RestorGenex's chief scientific officer, will present scientific data on the Company's proprietary RES-529 program in oncology. Dr. Sherris' presentation at the American Association for Cancer Research Conference on Targeting the PI3K-mTOR Network in Cancer is scheduled for Monday, September 15, 2014 at 4:30 pm (EST) at the Sheraton Philadelphia Downtown Hotel, Philadelphia, Pennsylvania.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.
RestorGenex Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 3:05PM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of June 30, 2014 and its financial results for the second quarter of 2014.
